Total Payments
$503,966
2024 Payments
$33,276
Companies
64
Transactions
459
Payment Breakdown by Category
Consulting$399,937 (79.4%)
Other$51,808 (10.3%)
Travel$45,131 (9.0%)
Food & Beverage$6,938 (1.4%)
Education$153.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $399,937 | 173 | 79.4% |
| Travel and Lodging | $45,131 | 133 | 9.0% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $31,128 | 17 | 6.2% |
| Honoraria | $20,680 | 9 | 4.1% |
| Food and Beverage | $6,938 | 124 | 1.4% |
| Education | $153.00 | 3 | 0.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Regeneron Healthcare Solutions, Inc. | $86,205 | 79 | $0 (2023) |
| Amgen Inc. | $49,579 | 44 | $0 (2024) |
| PFIZER INC. | $22,085 | 18 | $0 (2024) |
| GENZYME CORPORATION | $21,563 | 10 | $0 (2024) |
| Novo Nordisk AS | $18,421 | 11 | $0 (2018) |
| Otsuka America Pharmaceutical, Inc. | $17,285 | 17 | $0 (2022) |
| Novo Nordisk Inc | $16,277 | 12 | $0 (2020) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $16,275 | 17 | $0 (2024) |
| Vertex Pharmaceuticals Incorporated | $14,880 | 11 | $0 (2023) |
| Janssen Biotech, Inc. | $14,690 | 23 | $0 (2022) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $33,276 | 24 | Amgen Inc. ($11,500) |
| 2023 | $33,007 | 19 | GENZYME CORPORATION ($11,190) |
| 2022 | $70,841 | 46 | Regeneron Healthcare Solutions, Inc. ($12,238) |
| 2021 | $67,317 | 37 | Regeneron Healthcare Solutions, Inc. ($17,689) |
| 2020 | $31,361 | 15 | GlaxoSmithKline, LLC. ($7,250) |
| 2019 | $85,096 | 106 | PFIZER INC. ($12,115) |
| 2018 | $87,084 | 107 | Regeneron Healthcare Solutions, Inc. ($28,913) |
| 2017 | $95,985 | 105 | Amgen Inc. ($30,121) |
All Payment Transactions
459 individual payment records from CMS Open Payments — Page 1 of 19
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/31/2024 | BioMarin Pharmaceutical Inc. | VOXZOGO 1.2mg (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,350.00 | General |
| Category: Achondroplasia | ||||||
| 12/19/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | — | Travel and Lodging | In-kind items and services | $194.07 | General |
| 12/19/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | — | Food and Beverage | In-kind items and services | $39.37 | General |
| 12/19/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | — | Food and Beverage | In-kind items and services | $39.37 | General |
| 12/19/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | — | Food and Beverage | In-kind items and services | $24.41 | General |
| 12/19/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | — | Food and Beverage | In-kind items and services | $24.41 | General |
| 12/11/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | — | Consulting Fee | Cash or cash equivalent | $5,100.00 | General |
| 12/11/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | — | Travel and Lodging | In-kind items and services | $140.00 | General |
| 12/11/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | — | Food and Beverage | In-kind items and services | $35.00 | General |
| 12/10/2024 | PFIZER INC. | ELREXFIO (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,350.00 | General |
| Category: ONCOLOGY | ||||||
| 12/09/2024 | Gilead Sciences, Inc. | Biktarvy (Drug) | Consulting Fee | Cash or cash equivalent | $1,180.00 | General |
| Category: HIV | ||||||
| 11/19/2024 | Johnson & Johnson Health Care Systems Inc. | SPRAVATO (Drug) | Consulting Fee | Cash or cash equivalent | $1,095.00 | General |
| Category: Neuroscience | ||||||
| 11/06/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | — | Travel and Lodging | In-kind items and services | $891.39 | General |
| 10/23/2024 | BioMarin Pharmaceutical Inc. | — | Food and Beverage | In-kind items and services | $64.95 | General |
| 07/30/2024 | Amgen Inc. | LUMAKRAS (Drug) | Consulting Fee | Cash or cash equivalent | $2,000.00 | General |
| Category: Oncology | ||||||
| 06/26/2024 | SANOFI PASTEUR INC. | — | Consulting Fee | Cash or cash equivalent | $1,578.00 | General |
| 06/15/2024 | BioMarin Pharmaceutical Inc. | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $900.00 | General |
| 06/06/2024 | Incyte Corporation | OPZELURA (Drug) | Consulting Fee | Cash or cash equivalent | $2,227.50 | General |
| Category: Dermatology | ||||||
| 05/22/2024 | Amgen Inc. | — | Consulting Fee | Cash or cash equivalent | $3,500.00 | General |
| 05/21/2024 | Amgen Inc. | — | Consulting Fee | Cash or cash equivalent | $3,500.00 | General |
| 05/21/2024 | Amgen Inc. | — | Travel and Lodging | Cash or cash equivalent | $2,500.00 | General |
| 05/07/2024 | GENZYME CORPORATION | — | Consulting Fee | Cash or cash equivalent | $1,315.00 | General |
| 04/10/2024 | GENZYME CORPORATION | — | Consulting Fee | Cash or cash equivalent | $1,227.50 | General |
| 01/04/2024 | Chiesi USA, Inc. | ELFABRIO (Drug) | Honoraria | Cash or cash equivalent | $3,000.00 | General |
| Category: ERT FOR FABRY DISEASE | ||||||
| 11/08/2023 | Vertex Pharmaceuticals Incorporated | — | Consulting Fee | Cash or cash equivalent | $800.00 | General |
About Dr. Michael Fine, M.D
Dr. Michael Fine, M.D is a Health Maintenance Organization healthcare provider based in Laguna Beach, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 11/16/2013. The National Provider Identifier (NPI) number assigned to this provider is 1346670007.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Michael Fine, M.D has received a total of $503,966 in payments from pharmaceutical and medical device companies, with $33,276 received in 2024. These payments were reported across 459 transactions from 64 companies. The most common payment nature is "Consulting Fee" ($399,937).
Ad
Practice Information
- Specialty Health Maintenance Organization
- Location Laguna Beach, CA
- Active Since 11/16/2013
- Last Updated 11/16/2013
- Taxonomy Code 302R00000X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1346670007
Products in Payments
- DUPIXENT (Biological) $51,592
- DUPIXENT DUPILUMAB INJECTION (Biological) $23,600
- Victoza (Drug) $18,909
- Xultophy 100/3.6 (Drug) $12,049
- LIBTAYO CEMIPLIMAB-RWLC INJECTION (Biological) $11,777
- KEVZARA SARILUMAB INJECTION (Biological) $10,136
- REXULTI (Drug) $7,100
- Dasotraline (Drug) $6,418
- REMICADE (Biological) $5,776
- Neulasta (Biological) $5,311
- Yescarta (Drug) $5,140
- XARELTO (Drug) $4,812
- JCAR017 (Drug) $4,800
- Tremfya (Drug) $4,760
- NO PRODUCT DISCUSSED (Drug) $4,720
- Non-Covered Product (Drug) $4,707
- OPZELURA (Drug) $4,703
- NUCALA (Biological) $4,640
- ILARIS (Biological) $4,568
- OCREVUS (Biological) $4,527
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.